Renal drug transporters and their significance in drug-drug interactions

被引:140
作者
Yin, Jia [1 ]
Wang, Joanne [1 ]
机构
[1] Univ Washington, Dept Pharmaceut, H272J Hlth Sci Bldg, Seattle, WA 98195 USA
关键词
Renal drug transporters; Drug-drug interactions; Organic cations; Organic anions; Nephrotoxicity; ORGANIC ANION TRANSPORTER; CISPLATIN-INDUCED NEPHROTOXICITY; MULTIDRUG-RESISTANCE PROTEINS; INTESTINAL P-GLYCOPROTEIN; KIDNEY PROXIMAL TUBULES; CATION TRANSPORTER-2; FUNCTIONAL-CHARACTERIZATION; CLINICAL PHARMACOKINETICS; MOLECULAR-IDENTIFICATION; TISSUE DISTRIBUTION;
D O I
10.1016/j.apsb.2016.07.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The kidney is a vital organ for the elimination of therapeutic drugs and their metabolites. Renal drug transporters, which are primarily located in the renal proximal tubules, play an important role in tubular secretion and reabsorption of drug molecules in the kidney. Tubular secretion is characterized by high clearance capacities, broad substrate specificities, and distinct charge selectivity for organic cations and anions. In the past two decades, substantial progress has been made in understanding the roles of transporters in drug disposition, efficacy, toxicity and drug-drug interactions (DDIs). In the kidney, several transporters are involved in renal handling of organic cation (OC) and organic anion (OA) drugs. These transporters are increasingly recognized as the target for clinically significant DDIs. This review focuses on the functional characteristics of major human renal drug transporters and their involvement in clinically significant DDIs. (C) 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
引用
收藏
页码:363 / 373
页数:11
相关论文
共 50 条
[41]   Semantic Inference for Pharmacokinetic Drug-Drug Interactions [J].
Moitra, Abha ;
Palla, Ravi ;
Tari, Luis ;
Krishnamoorthy, Mukkai .
2014 IEEE INTERNATIONAL CONFERENCE ON SEMANTIC COMPUTING (ICSC), 2014, :92-95
[42]   Drug-drug interactions in pediatric oncology patients [J].
Balk, T. E. ;
van der Sijs, I. H. ;
van Gelder, T. ;
Janssen, J. J. B. ;
van der Sluis, I. M. ;
van Leeuwen, R. W. F. ;
Engels, F. K. .
PEDIATRIC BLOOD & CANCER, 2017, 64 (07)
[43]   Network Based Prediction of Drug-Drug Interactions [J].
Gunawardena, S. D. L. ;
Weerasinghe, A. R. ;
Wijesinghe, M. W. A. C. R. .
2017 17TH INTERNATIONAL CONFERENCE ON ADVANCES IN ICT FOR EMERGING REGIONS (ICTER) - 2017, 2017, :78-85
[44]   Drug-drug interactions you should know! [J].
Voigt, Niels ;
Ort, Katharina ;
Sossalla, Samuel .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (04) :264-275
[45]   STUDY OF IDENTIFICATION AND ASSESSMENT OF DRUG-DRUG INTERACTIONS [J].
Shekar, H. S. ;
Chandrashekhar, H. R. ;
Bhagawan, B. C. ;
Alirezasahebdel .
JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2014, 3 (06) :1373-1378
[46]   Drug-drug interactions involving antipsychotics and antihypertensives [J].
Buzea, Catalin Adrian ;
Dima, Lorena ;
Correll, Christoph U. ;
Manu, Peter .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (04) :285-298
[47]   Drug-drug interactions that interfere with statin metabolism [J].
Hirota, Takeshi ;
Ieiri, Ichiro .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (09) :1435-1447
[48]   Drug-Drug Interactions in Cardiovascular Catheterizations and Interventions [J].
Dunn, Steven P. ;
Holmes, David R., Jr. ;
Moliterno, David J. .
JACC-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (12) :1195-1208
[49]   Identification of Drug-Drug Interactions Using OCR [J].
Alrehily, Enas Saleem ;
Alhejaili, Rawan Fahad ;
Albeladi, Dalal Rasheed ;
Syed, Liyakathunisa .
IOT TECHNOLOGIES FOR HEALTH CARE, HEALTHYIOT 2021, 2022, 432 :125-135
[50]   Analysis of drug-drug interactions in patients with HIV and metabolic syndrome [J].
Tuan, Jessica ;
Igiraneza, Grace ;
Ogbuagu, Onyema .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (10) :953-965